Top diabetic drug goes off patent, prices to fall by 3rd

Top diabetic drug goes off patent, prices to fall by 3rd The growing anti-diabetes market, valued at about Rs 17,000 crore, is set to witness action with generic versions of US firm Merck’s blockbuster Januvia being launched, reducing the cost of therapy by a third. This is on the heels of Sitagliptin, a relatively newer but vital anti-diabetic drug, losing patent protection in July. https://ift.tt/fKYdTp2